ARTICLE | Clinical News
TG1042: Phase I/II started
October 19, 2015 7:00 AM UTC
Ascend began an open-label, Australian Phase I/II trial to evaluate weekly intratumoral injections of ASN-002 in up to 36 patients prior to surgical tumor excision. Patients will receive ASN-002 for 3...